LIPO - Multiplikator Forward P/S Lipella Pharmaceuticals
The projected P/S metric demonstrates the current market valuation of Lipella Pharmaceuticals (LIPO), and the indicator has reached the level of 7.30. This trend reflects management's focus on local inflammation treatment and urology. However, reliance on secondary offerings and the risk of early-stage test failures create high volatility. Team stability is maintained through a flexible culture and stock option programs for the scientists developing niche drugs.
Lipella Pharma (LIPO) - rincian metrik lan laporan keuangan
- rega pasar lan target rega analis:
- statistik kapitalisasi pasar:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Utang marang Ekuitas Lipella Pharmaceuticals|LIPO - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Lipella Pharmaceuticals|LIPO - Utang perusahaan|Utang-utang marang kapitalisasi buku Lipella Pharma|LIPO - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Lipella Pharmaceuticals|Likuiditas cepet lipella.com
- data bathi bisnis lan rasio investasi:
LIPO - Bathi sawise pajeg|Proyeksi bathi mangsa ngarep Lipella Pharmaceuticals|LIPO - Nilai perusahaan marang bathi resik|Pangali Forward P/E Lipella|LIPO - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Lipella Pharma|LIPO - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Lipella Pharmaceuticals|LIPO - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan lipella.com|LIPO - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Lipella Pharmaceuticals
- informasi babagan volume dodolan lan pendapatan:
Ringkesan analitik perusahaan:Lipella Pharmaceuticals, Inc. LIPO
Forward P/S determines the market value of a business relative to expected sales volumes, allowing investors to identify overvalued assets and filter out speculative noise. The trend of the forward P/S valuation for Lipella Pharmaceuticals (LIPO) helps align market expectations with the actual costs of implementing ESG standards and the environmental modernization of laboratories, both of which impact the ultimate efficiency of revenue scaling.
Pesaing Lipella Pharmaceuticals
Rasio rega marang prakiraan pendapatan Haleon HLN|Kenvue Inc - Rasio rega marang prakiraan pendapatan|Verona Pharma Corp - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Jyong Bio MENS|Ligand Pharmaceuticals (LGND) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan AMRX (amneal.com)|PRGO (Perrigo) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Alvotech S.A. ALVO|Rasio rega marang prakiraan pendapatan Liquidia Technologies (LQDA)|Rasio rega marang prakiraan pendapatan GLPG (Galapagos Corp)|Rasio rega marang prakiraan pendapatan ANI Pharmaceuticals ANIP|mannkindcorp.com - Rasio rega marang prakiraan pendapatan|Amphastar Pharmaceuticals, Inc. - Multiplikator Forward P/S|PCRX - Multiplikator Forward P/S|SPRY (ARS Pharma) - Multiplikator forward rega marang pendapatan|Theravance Corp - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Aquestive Therapeutics|scPharma - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S TECX|TNXP (Tonix Pharma) - Rega forward marang dodolan|Multiplikator Forward P/S SXTC (China SXT Pharmaceuticals, Inc.)|Multiplikator Forward P/S Eupraxia Pharmaceuticals, Inc. EPRX|BHST - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan EXOZ (invizyne.com)|oramed.com (ORMP) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Entera Bio|HYFT (MindWalk) - Multiplikator Forward P/S|Multiplikator Forward P/S ABVC BioPharma, Inc|Multiplikator Forward P/S CPIX|Multiplikator forward rega marang pendapatan quantumbiopharma.com QNTM|Multiplikator Forward P/S FGEN (FibroGen)|Telomir Pharmaceuticals Inc (TELO) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RANI: Multiplikator forward rega marang pendapatan|SNYR - Multiplikator Forward P/S|RLYB (rallybio.com) - Multiplikator forward rega marang pendapatan|LEXX: Rasio rega marang pendapatan sing dikarepake|PULM (Pulmatrix) - Multiplikator Forward P/S|Pheton (PTHL) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S APM|Multiplikator forward rega marang pendapatan Lyra Therapeutics Inc LYRA|Multiplikator Forward P/S IBO (Impact BioMedical Inc)|Multiplikator Forward P/S TNF Pharmaceuticals Inc. TNFA|YCBD - Rasio rega marang prakiraan pendapatan|PRFX: Rasio rega marang prakiraan pendapatan|altamiratherapeutics.com (CYTO) - Rasio rega marang prakiraan pendapatan|OPTN - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Pieris Pharmaceuticals|Rasio rega marang prakiraan pendapatan PROC|Multiplikator Forward P/S PTPI|Rasio kapitalisasi marang dodolan sing dikarepake Qilian International Holding Group|Rasio rega marang prakiraan pendapatan ACELYRIN, Inc. SLRN|TFFP (TFF Pharmaceuticals, Inc) - Rega mangsa ngarep marang pendapatan
